Over a Baltimore Crab Cake Platter, Our Tech Guru Told Me About This Surging Biotech
Today marks exactly two months since we recommended Emergent BioSolutions Inc. (NYSE: EBS) – which we pitched as an “immunotherapy stock with a twist.”
In that short stretch, Emergent is up 25.5%. That’s an annualized return of 153%.
And there’s more to come…